Lowest Price Guaranteed From USD 4,899
Published
April 2020
Pages
122
View Count
25394
Example Insights
Report Description
[COVID-19 SERIES] New coronavirus (COVID-19) is a previously unidentified strain of coronavirus, that first emerged in the Chinese city of Wuhan in December 2019. The virus belongs to the same family as the virus that causes severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). On 30th January 2020, the World Health Organization (WHO) declared the coronavirus outbreak as a global health emergency. In fact, the virus is estimated to have infected more than 45,000 individuals, around the globe (estimates till the second week of February 2020). In order to deal with this outbreak and prevent the spread of virus to new geographies, countries are adopting various precautions.
The WHO has recently released the Strategic Preparedness and Response Plan (SPRP) that lays out activities and resources needed by international health organizations globally, including WHO, to implement priority public health measures in support of countries to prepare and respond to COVID-19 for a period between February to April 2020.
More than 35 pharmaceutical / biotechnology companies, government agencies, and research institutes have disclosed research programs focused on developing vaccines / drugs to prevent or treat COVID-19 infections. In addition, close to 250 diagnostic tests are currently available / being developed for effective diagnosis of patients. The rising healthcare burden of the disease has also attracted significant funding to fuel drug development efforts in this space; recent funding initiatives include USD 100 million funding by Bill & Melinda Gates Foundation, and USD 26 million vaccine development fund by the UK government.
Several recent developments have taken place in the field of noval coronavirus COVID-19. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development” report features an extensive study of the vaccine / drug candidates and diagnostic tests being investigated for COVID-19 infection prevention, treatment and diagnosis. Amongst other elements, the report includes:
Elaborate profiles of the key players involved in vaccine / drug and diagnostic development. Each profile features a brief overview of the company, information on its development programs, details related to funding, and collaborations related to COVID-19.
Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
2.2. COVID-19: List of Drugs and Vaccines Developers
2.3. Key Developers
2.3.1. AbbVie
2.3.2. AbCellera / Eli Lilly
2.3.3. Ascletis Pharmaceuticals
2.3.4. Baylor College of Medicine
2.3.5. BenevolentAI
2.3.6. Biocryst Pharma
2.3.7. BioNTech / Pfizer
2.3.8. CIPLA
2.3.9. Clover Biopharmaceuticals / GSK
2.3.10. CureVac
2.3.11. CytoDyn
2.3.12. Deragen / Dankook University / Emory University
2.3.13. EastGate Biotech
2.3.14. GeoVax / BravoVax
2.3.15. Gilead Sciences
2.3.16. Heat Biologics
2.3.17. Imperial College London
2.3.18. Inovio Pharmaceuticals
2.3.19. InSilico Medicne
2.3.20. Jenner Institute
2.3.21. Johnson and Johnson
2.3.22. Moderna Therapeutics
2.3.23. NanoViricides
2.3.24. Novavax
2.3.25. Regeneron Pharmaceuticals
2.3.26. Regeneron Pharmaceuticals / Sanofi
2.3.27. ShanghaiTech University
2.3.28. Sirnaomics
2.3.29. Tongji University / Stemirna Therapeutics
2.3.30. University of Queensland
2.3.31. Vaxart
2.3.32. Vir Biotechnology
2.3.33. Vir Biotechnology / Alnylam Pharmaceuticals
2.3.34. Takeda
2.4. COVID-19 Pipeline: Analysis
2.4.1. COVID-19 Pipeline: Analysis by Location of Headquarters
2.4.2. COVID-19 Pipeline: Analysis by Type of Candidate
2.4.3. COVID-19 Pipeline: Analysis by Type of Candidate and Drug Development Approach
2.4.4. COVID-19 Pipeline: Analysis by Development Status
2.4.5. COVID-19 Pipeline: Analysis by Type of Drug Class
3. COVID-19: DIAGNOSTICS CURRENT MARKET LANDSCAPE
3.1. Chapter Overview
3.2. COVID-19: List of Diagnostic Developers
3.2.1. COVID-19 Diagnostic Tests: Analysis by Developer Headquarters
3.2.2. COVID-19 Diagnostic Tests: Analysis by Test Application
3.2.3. COVID-19 Diagnostic Tests: Analysis by Development Status
3.2.4. COVID-19 Diagnostic Tests: Analysis by Type of Assay
3.2.5. COVID-19 Diagnostic Tests: Analysis by Type of Technique
3.2.6. COVID-19 Diagnostic Tests: Analysis by Regulatory Compliance
4. FUNDING AND INVESTMENT ANALYSIS
4.1. Chapter Overview
4.2. COVID-19: List of Funding Instances
4.2.1. COVID-19: Analysis by Cumulative Number of Instances
4.2.2. COVID-19: Analysis by Cumulative Amount Invested
4.2.3. COVID-19: Analysis by Purpose of Funding
5. ACADEMIC GRANTS ANALYSIS
5.1. Chapter Overview
5.2. Scope and Methodology
5.3. COVID-19: Academic Grant Analysis
5.3.1. Analysis by Year of Award
5.3.2. Analysis by Amount Awarded
5.3.3. Analysis by Administering Institute Center
5.3.4. Analysis by Support Period
5.3.5. Analysis by Funding Institute Center and Support Period
5.3.6. Analysis by Funding Mechanism
5.3.7. Analysis by Type of Grant Application
5.3.8. Popular NIH Departments
5.3.9. Analysis by Type of Recipient Organization
5.3.10. Popular Recipient Organizations
5.3.11. Analysis By Grant Mechanism
5.3.12. Prominent Program Officers
5.3.13. Regional Distribution of Recipient Organization
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. COVID-19: List of Interventional Trials
6.3.1. Analysis by Trial Status
6.3.2. Analysis by Trial Phase
6.3.3. Analysis by Study Design
6.3.4. Analysis by Type of Sponsor / Collaborator
6.3.5. Geographical Analysis by Number of Clinical Trials
6.3.6. Geographical Analysis by Enrolled Patient Population
6.4. COVID-19: List of Observational Trials
7. SOCIAL MEDIA ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Corona Virus: Trends on Twitter
7.3.1. Cumulative Week-wise Activity by Volume of Tweets
7.3.2. Historical Trends in Volume of Tweets
7.3.3. Trending Words / Phrases on Twitter
7.3.4. Most Prolific Contributors on Twitter
7.4. Prevalent Trends Related to Coronavirus
7.4.1. Ongoing Developments
7.4.2. Key Historical Trends
7.4.3. Geographical Activity
7.5. Concluding Remarks
8. RECENT UPDATES
8.1. Chapter Overview
8.2. Therapeutics and Vaccines Development
8.3. Funding
8.4. Diagnostics
9 APPENDIX 1: TABULATED DATA
10 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 COVID-19 Therapeutics / Vaccines Pipeline: Distribution by Developer Headquarters
Figure 2.2 COVID-19 Therapeutics / Vaccines Pipeline: Distribution by Type of Candidate
Figure 2.3 COVID-19 Therapeutics / Vaccines Pipeline: Distribution by Drug Development Approach
Figure 2.4 COVID-19 Therapeutics / Vaccines Pipeline: Distribution by Phase of Development
Figure 2.5 COVID-19 Therapeutics Pipeline: Distribution by Type of Drug Class
Figure 2.6 COVID-19 Therapeutics Vaccines Pipeline: Distribution by Type of Drug Class
Figure 3.1 COVID-19 Diagnostics Tests: Distribution by Developer Headquarters
Figure 3.2 COVID-19 Diagnostics Tests: Distribution by Test Application
Figure 3.3 COVID-19 Diagnostics Tests: Distribution by Development Status
Figure 3.4 COVID-19 Diagnostic Tests: Distribution by Type of Test
Figure 3.5 COVID-19 Diagnostic Tests: Distribution by Test Specifications
Figure 3.6 COVID-19 Diagnostic Tests: Distribution by Regulatory Compliance
Figure 4.1 Funding and Investment Analysis: Cumulative Number of Funding Instances
Figure 4.2 Funding and Investment Analysis: Cumulative Amount Invested, (USD Million)
Figure 4.3 Funding and Investment Analysis: Distribution by Purpose of Funding
Figure 4.4 Funding and Investment Analysis: Most Active Investors
Figure 5.1 Grant Analysis: Cumulative Trend by Year of Projects
Figure 5.2 Grant Analysis: Cumulative Trend by Amount Awarded
(USD Million)
Figure 5.3 Grant Analysis: Distribution by Administering Institute Center
Figure 5.4 Grant Analysis: Distribution by Support Period
Figure 5.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 5.6 Grant Analysis: Distribution by Funding Mechanism
Figure 5.7 Grant Analysis: Distribution by Type of Grant Application
Figure 5.8 Grant Analysis: Popular NIH Departments
Figure 5.9 Grant Analysis: Type of Recipient Organization
Figure 5.10 Grant Analysis: Popular Recipient Organizations
Figure 5.11 Grant Analysis: Popular Grant Mechanism
Figure 5.12 Grant Analysis: Prominent Program Officers
Figure 5.13 Top Program Officers: Distribution by Number of Grants and Amount Awarded
Figure 5.14 Grant Analysis: Regional Distribution of Recipient Organization
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3 Clinical Trial Analysis: Distribution of Patient Enrollment and Trial Phase
Figure 6.4 Clinical Trial Analysis: Distribution by Study Design
Figure 6.5 Clinical Trial Analysis: Top Sponsors
Figure 6.6 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 6.7 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.1 Social Media Analysis: Cumulative Year-Wise Activity by Volume of Tweets
Figure 7.2 Social Media Analysis: Historical Trends on Twitter
Figure 7.3 Social Media Analysis: Trending Words / Phrases on Twitter
Figure 7.4 Social Media Analysis: Most Prolific Contributors on Twitter
Figure 7.5 Ongoing Developments: Google News
Figure 7.6 Historical Timeline: Analysis of Google Trends
Figure 7.7 Geographical Activity: Analysis of Google Trend
Table 2.1 COVID-19: List of Drugs and Vaccine Developers
Table 2.2 COVID-19 Clinical Trials: lopinavir
Table 2.3 COVID-19 Clinical Trials: remdesivir
Table 2.4 COVID-19: List of Recently Identified Therapeutics / Vaccines
Table 3.1 COVID-19: List of Diagnostics Tests
Table 3.2 COVID-19: Details of Diagnostics Tests
Table 4.1 COVID-19: List of Funding and Investments
Table 6.1 COVID-19: List of Interventional Trials
Table 6.2 COVID-19: List of Sponsors
Table 6.3 COVID-19: List of Observational Trials
Table 9.1 COVID-19 Therapeutics / Vaccine Pipeline: Distribution by Developers Headquarter
Table 9.2 COVID-19 Therapeutics / Vaccine Pipeline: Distribution by Type of Candidate
Table 9.3 COVID-19 Therapeutics / Vaccine Pipeline: Distribution by Drug Development Approach
Table 9.4 COVID-19 Therapeutics / Vaccine Pipeline: Distribution by Phase of Development
Table 9.5 COVID-19 Therapeutics Pipeline: Distribution by Type of Drug Class
Table 9.6 COVID-19 Therapeutics / Vaccine Pipeline: Distribution by Type of Vaccine
Table 9.7 COVID-19 Diagnostics Tests: Distribution by Developer Headquarters
Table 9.8 COVID-19 Diagnostics Tests: Distribution by Test Application
Table 9.9 COVID-19 Diagnostics Tests: Distribution by Development Status
Table 9.10 COVID-19 Diagnostics Tests: Distribution by Type of Test
Table 9.11 COVID-19 Diagnostics Tests: Distribution by Test Specifications
Table 9.12 COVID-19 Diagnostics Tests: Distribution by Regulatory Compliance
Table 9.13 COVID-19 Funding and Investment Analysis: Cumulative Number of Instances
Table 9.14 COVID-19 Funding and Investment Analysis: Cumulative Amount Invested, (USD Million)
Table 9.15 COVID-19 Funding and Investment Analysis: Distribution by Purpose of Funding
Table 9.16 COVID-19 Funding and Investment Analysis: Most Active Investors
Table 9.17 Grant Analysis: Cumulative Trend by Year of Projects
Table 9.18 Grant Analysis: Trend by Amount Awarded (USD Million)
Table 9.19 Grant Analysis: Distribution by Administering Institute Center
Table 9.20 Grant Analysis: Distribution by Support Period
Table 9.21 Grant Analysis: Distribution by Funding Institute Center and Support Period
Table 9.22 Grant Analysis: Distribution by Funding Mechanism
Table 9.23 Grant Analysis: Distribution by Type of Grant Application
Table 9.24 Grant Analysis: Popular NIH Departments
Table 9.25 Grant Analysis: Type of Recipient Organization
Table 9.26 Grant Analysis: Popular Recipient Organization
Table 9.27 Grant Analysis: Popular Funding Mechanism
Table 9.28 Clinical Trial Analysis: Distribution by Trial Status
Table 9.29 Clinical Trial Analysis: Distribution by Trial Phase
Table 9.30 Clinical Trial Analysis: Distribution of Patient Enrollment and Trial Phase
Table 9.31 Clinical Trial Analysis: Top Sponsors
Table 9.32 Social Media Analysis: Cumulative Year-Wise Activity by Volume of Tweets
The following companies and organizations have been mentioned in the report.